GlassScriptPhysician profile
Salvatore Dicarlo
NPI 1356388508
$1,626.78
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.34 · 2020: $179 · 2021: $475 · 2022: $889.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $797.72 | 2021-2022 | |
| Corium, LLC | $235.94 | 2022 | |
| Tris Pharma INC | $108.03 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $105.28 | 2019-2020 | |
| Neos Therapeutics, LP | $103.26 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.06 | 2020-2021 | |
| Cranial Technologies, INC | $59.74 | 2019-2022 | |
| Glaxosmithkline, LLC. | $40.80 | 2020-2021 | |
| Pfizer INC. | $37.07 | 2020-2022 | |
| Phadia US INC. | $18.45 | 2022 | |
| Adlon Therapeutics L.P. | $15.51 | 2021 | |
| Merck Sharp & Dohme LLC | $14.24 | 2020 | |
| Amgen INC. | $12.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salvatore Dicarlo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.